New study highlights the use of bivalirudin for anticoagulation in interventional cardiovascular procedures. The findings of the study are published in the journal Cardiovascular Innovations and Applications.
Anticoagulation is imperative to reduce the incidence of thrombotic complications in patients undergoing percutaneous interventional cardiovascular procedures; however, this is at the expense of increased risk of bleeding. The optimal anticoagulation strategy for these procedures remains unclear.
‘Clinical use of bivalirudin as an anticoagulant may help treat patients undergoing percutaneous coronary intervention and transcatheter aortic valve replacement procedures.’
Unfractionated heparin is the most commonly used anticoagulant during interventional procedures, but has several limitations, such as a relatively high incidence of bleeding events, the occurrence of heparin-induced thrombocytopenia, and a paradoxical thrombotic effect.
Contemporary studies have demonstrated that bivalirudin decreases the occurrence of bleeding complications, but potentially increases the risk of acute stent thrombosis.
The authors discuss the pharmacology of bivalirudin and its current clinical application in patients undergoing percutaneous coronary intervention and transcatheter aortic valve replacement procedures.